BioCentury | Sep 26, 2011
Clinical News

TV1001: Phase I data

...of 80 mg oral TV1001 were safe with no significant increases in methemoglobin levels, which TheraVasc...
...The company plans to complete Phase IIa trials of TV1001 in the indication in mid-2012. TheraVasc Inc....
Items per page:
1 - 1 of 1
BioCentury | Sep 26, 2011
Clinical News

TV1001: Phase I data

...of 80 mg oral TV1001 were safe with no significant increases in methemoglobin levels, which TheraVasc...
...The company plans to complete Phase IIa trials of TV1001 in the indication in mid-2012. TheraVasc Inc....
Items per page:
1 - 1 of 1